Extended Partnership with NecstGen

Extended Partnership with NecstGen

Pan Cancer T, a preclinical biotech focussing on the development of next-generation TCR-T treatments, has extended its collaboration with Leiden based NecstGen to include the development and clinical manufacturing of retroviral vectors. The parties have agreed to...
4.25 Million in Seed Extension Round

4.25 Million in Seed Extension Round

Rotterdam, July 11 2024 Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension round. This round includes a new investor InnovationQuarter and...
Awarded the Seal of Excellence from the European Commission

Awarded the Seal of Excellence from the European Commission

Amongst a record number of applicants, Pan Cancer T’s EIC Accelerator proposal has been awarded the Seal of Excellence. The EIC Accelerator Seal of Excellence and the EIC Transition activities Seal of Excellence are quality labels awarded to project proposals...